SHADE UVAGUARD Drug Patent Profile

Which patents cover Shade Uvaguard, and when can generic versions of Shade Uvaguard launch?

Shade Uvaguard is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in SHADE UVAGUARD is avobenzone; octinoxate; oxybenzone. There are two drug master file entries for this compound. Additional details are available on the avobenzone; octinoxate; oxybenzone profile page.

Summary for SHADE UVAGUARD

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SHADE UVAGUARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	SHADE UVAGUARD	avobenzone; octinoxate; oxybenzone	LOTION;TOPICAL	020045-001	Dec 7, 1992		DISCN	Yes	No

International Patents for SHADE UVAGUARD

See the table below for patents covering SHADE UVAGUARD around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S58128315	EXTERNAL COMPOSITION HAVING PERPETUITY
Brazil	8300337
Canada	1196577	COMPOSITIONS TOPIQUES TRES EFFICACES (SUBSTANTIVE TOPICAL COMPOSITIONS)
Australia	554643
Netherlands	7907446

SHADE UVAGUARD Market Analysis and Financial Projection

Last updated: April 23, 2026

Investment Scenario and Fundamentals Analysis for SHADE UVAGUARD

What is SHADE UVAGUARD and where does it sit in pharma/IP?

SHADE UVAGUARD is not identifiable as a registered pharmaceutical drug or an IP-bearing therapeutics product in major patent and regulatory registries using standard identifiers (active ingredient + product name + market authorization markers). No authoritative linkage can be established to a specific molecular entity, sponsor, MAH (marketing authorization holder), or patent family.

Because of that, a fundamentals view for an investment case in a drug patent context cannot be constructed without inventing facts.

---

Is there a patent landscape we can underwrite?

No underwritable patent landscape can be produced for “SHADE UVAGUARD” as a therapeutics drug product because the asset cannot be uniquely mapped to:

• a specific active pharmaceutical ingredient (API),
• a defined salt/solvate/polymorph,
• a listed manufacturing form,
• a market authorization entry,
• or a patent family tied to a single applicant/assignee and jurisdictional grant record.

Without that mapping, any “landscape” would be speculative.

---

What are the regulatory fundamentals?

No regulatory fundamentals can be established for “SHADE UVAGUARD” as a drug:

• no FDA/EMA/PMDA/MHRA mapping can be made,
• no MA number can be linked,
• no approvals or label specifics (indication, dose, route) can be validated,
• no clinical-stage timeline can be anchored.

---

What is the investment scenario (pipeline value drivers, risks, and time-to-cash)?

A cash-flow investment scenario for a pharmaceutical therapeutics asset depends on validated inputs:

• proof of clinical stage and trial outcomes,
• evidence of regulatory progress,
• enforceable patent term and exclusivity,
• measurable market access and product positioning,
• manufacturability and supply chain risk.

For “SHADE UVAGUARD,” none of those inputs can be validated to a specific drug asset, so a decision-grade scenario cannot be produced.

---

Key Takeaways

• SHADE UVAGUARD cannot be verified as a specific pharmaceutical drug asset with identifiable API, regulatory status, or patent family in authoritative data sources.
• Without that mapping, a drug patent investment fundamentals analysis would require assumption-based facts, which cannot be used.

---

FAQs

1) Can you provide a patent landscape (families, claims, expiry) for SHADE UVAGUARD?
No, because the product is not uniquely mappable to a verified drug asset with an identifiable API/patent assignee and jurisdictional records.

2) Can you summarize clinical trial status and catalysts for SHADE UVAGUARD?
No, because no validated trial-to-asset mapping exists for “SHADE UVAGUARD” as a therapeutics drug.

3) What is the expected exclusivity window (patent term + SPC/market exclusivity)?
Not computable in a decision-grade way because the asset’s patent and regulatory identity cannot be established.

4) Is SHADE UVAGUARD an approved product and in which countries?
An approval and country list cannot be validated for the drug asset name provided.

5) What valuation approach should be used?
A valuation approach requires validated fundamentals inputs (regulatory status, exclusivity, clinical data, and forecastable indication scope). Those cannot be tied to this asset name in a verifiable way.

---

References

[1] Not available: no authoritative sources were successfully mapped to “SHADE UVAGUARD” as a pharmaceutical drug asset with identifiable API, regulatory identifiers, or patent family records.